Oxford Genetics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. Ryan Cawood, founder and chief executive of Oxford Genetics, said: “2018 was an outstanding year for our business and we are expecting to close our financial year to 30 April 2019 showing 300% revenue growth on the prior year. The company has already begun to develop a new generation of gene-editing technology that can be used in human clinical trials and is working with partners on developing an additional type of gene therapy. The remaining agreements are confidential deals secured with large pharmaceutical firms.
Oxford Genetics will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies. The company has already begun to develop a new generation of gene-editing technology that can be used in human clinical trials and is working with partners on developing an additional type of gene therapy. The remaining agreements are confidential deals secured with large pharmaceutical firms.